SpA & Pregnancy Outcomes? ➡️SpA pts txed w/ bDMARDs at conception are not at higher risk for adverse pregnancy outcomes compared to those w/o bDMARD ➡️Stopping bDMARDs after conception assoc w/ ↑ dz activity during pregnancy + after birth & ↑flares Abst#1730 #ACR21 @RheumNow https://t.co/Y4c7vI0cgS

All for one or one for all? Lumper or splitter? Highlight from #ACR21 was session 6S403 looking at axial involvement in AxSpa vs PsA. I share my thoughts here at https://t.co/i2nDvMklee @RheumNow https://t.co/62tRRiAcUJ

• Axial spondyloarthritis with psoriasis or psoriatic spondylitis | RheumNow

Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at

Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn

• Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors fo…

Work participation in patients with axSPA Patients w/ axSpA often have increased absence from work as well as reduced productivity at work, which can lead to wider economic & social burden. Dr. Dey (@DrMiniDey) discusses abstracts from #ACR21. https://t.co/eAMLPR2zoT https://t.co/NuIajGa7gx

• https://bit.ly/3BTBqXG

RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v

• Disease Activity and Outcome in Pregnancies of Patients with SpA - Data from th…

Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn

French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd

• More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an …

SERENA interim analysis on interruption of secukinumab in AS and PsA 🔹>=16 wks of Rx before interruption of >= 3 mo. 🔹75-80% of pts reinitiated w/o loading phase 🔹AS: BASDAI, PGA stable 🔹PsA: SJC, TJC returned to Rx baseline https://t.co/3G6rVW8TPv #ACR21 Abst#1361 @RheumNow

• Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patien…

Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pure PsA & pure axSpA but w/ a higher disease burden compared to both diseases, & lower use of b-DMARDs. Abs 1787 #ACR21 #ACRbest #RheumNow @RheumNow https://t.co/Wsysm7A0Y3 https://t.co/rwQ8ukBEDq

• What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden:…

5 yr multinational PROOF study - enrolled 1612 axSpA pts enrolled (65% xray+ axSpA; 35% nr-axSpA) nraxSpA had more enthesitis, PSO IBD. Over time, more TNFi use (less NSAIDs) w/ less disease activity #ACR21 Abst #0363 https://t.co/5DdDlCjq9h (Graph: NSAID use over time) https://t.co/5JE69vTIy9

• https://bit.ly/2Ytz18g

Pregnant pts w/ PsA, but not AxSpA, at increased risk of pre-eclampsia. In RA pregnancies, pre-eclampsia risk increases w/ dz severity prior/during pregnancy. We need to discuss potential risks w/ pts and OB team. Abs 1722 #ACR21 #RheumNow @RheumNow https://t.co/yeQmNAZ1jV https://t.co/cBfeVKQHfr

• Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatme…

Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802 https://t.co/QvyayelBYU https://t.co/50dNQm30vf

• https://bit.ly/3bWiQmZ

Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt